Page 836 - Read Online
P. 836
Bhangui et al. Hepatoma Res 2020;6:71 I http://dx.doi.org/10.20517/2394-5079.2020.67 Page 15 of 15
in an antigen presenting cell line. Clin Immunol 2013;148:44-55.
64. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic
cell activation. J Immunol 2012;189:558-66.
65. Pfiffer TEF, Seehofer D, Nicolaou A, Neuhaus R, Riess H, et al. Recurrent hepatocellular carcinoma in liver transplant recipients:
parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori 2011;97:436-41.
66. Roh YN, David Kwon CH, Song S, Shin M, Man Kim J, et al. The prognosis and treatment outcomes of patients with recurrent
hepatocellular carcinoma after liver transplantation. Clin Transplant 2014;28:141-8.
67. Guerrini GP, Berretta M, Tarantino G, Magistri P, Pecchi A, et al. Multimodal oncological approach in patients affected by recurrent
hepatocellular carcinoma after liver transplantation. Eur Rev Med Pharmacol Sci 2017;21:3421-35.
